Role of conventional ovarian screening is questioned
BMJ 1999; 318 doi: https://doi.org/10.1136/bmj.318.7183.605a (Published 27 February 1999) Cite this as: BMJ 1999;318:605
- Gordon Narayansingh, Gynaecological oncology fellow (DavidParkin@compuserve.com),
- Kheng Chew, Visiting specialist registrar,
- David Parkin, Consultant gynaecological oncologist
- Department of Gynaecological Oncology, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN
EDITOR—It is heartening to read Roylance and Waxman's personal view of cancer screening.1 They say that current screening schedules are predominantly subjective and are heavily based on individuals' interpretation, and proposed that we should pursue the path of molecular screening technologies.
Three postmenopausal women recently presented to our service with advanced ovarian cancer; of note was the fact that they had been evaluated for vaginal bleeding within the past six months. All three had had examination under anaesthesia, hysteroscopy, …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.